Merck & Co Inc
NYSE:MRK 3:27:50 PM EDT
Products
FDA Approves Keytruda As Adjuvant Treatment After Surgical Resection, Platinum-Based Chemotherapy
Published: 01/27/2023 12:08 GMT
Merck & Co Inc (MRK) - FDA Approves Keytruda® (pembrolizumab) As Adjuvant Treatment Following Surgical Resection and Platinum-based Chemotherapy for Patients With Stage Ib (t2a ≥4 Centimeters), Ii, Or Iiia Non-small Cell Lung Cancer (nsclc).
FDA Approves Keytruda® (pembrolizumab) As Adjuvant Treatment Following Surgical Resection and Platinum-based Chemotherapy for Patients With Stage Ib (t2a ≥4 Centimeters), Ii, Or Iiia Non-small Cell Lung Cancer (nsclc).
Merck & Co Inc - Two Fatal Adverse Reactions of Myocarditis Occurred in Keynote-091.
FDA Approves Keytruda® (pembrolizumab) As Adjuvant Treatment Following Surgical Resection and Platinum-based Chemotherapy for Patients With Stage Ib (t2a ≥4 Centimeters), Ii, Or Iiia Non-small Cell Lung Cancer (nsclc).
Merck & Co Inc - Two Fatal Adverse Reactions of Myocarditis Occurred in Keynote-091.